Journal Home
Search for

Volume 13, Issue 9, Pages 1016-1021 (September 2007)


View previous. 7 of 19 View next.

Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease

Kikuchi Takahide1, Pablo M. Parker2, Michael Wu3, William Y.K. Hwang4, Paul A. Carpenter13, Carina Moravec1, Barbara Stehr2, Paul J. Martin13, Perry Rosenthal5, Stephen J. Forman2, Mary E.D. Flowers13Corresponding Author Informationemail address

Received 21 March 2007; accepted 7 May 2007. published online 19 July 2007.

Abstract 

Keratoconjunctivitis sicca (KCS) occurs in 40%-60% of patients with chronic graft-versus-host-disease (cGVHD) after allogeneic hematopoietic cell transplantation. Although immunosuppressive therapy is the primary treatment of chronic GVHD, ocular symptoms require measures to improve ocular lubrication, decrease inflammation, and maintain mucosal integrity. The liquid corneal bandage provided by a fluid-ventilated, gas-permeable scleral lens (SL) has been effective in mitigating symptoms and resurfacing corneal erosions in patients with KCS related to causes other than cGVHD. We report outcomes in 9 consecutive patients referred for SL fitting for cGVHD-related severe KCS that was refractory to standard treatments. All patients reported improvement of ocular symptoms and reduced the use of topical lubricants after SL fitting resulting from decreased evaporation. No serious adverse events or infections attributable to the SL occurred. The median Ocular Surface Disease Index improved from 81 (75-100) to 21 (6-52) within 2 weeks after SL fitting, and was 12 (2-53) at the time of last contact, 1-23 months (median, 8.0) after SL fitting. Disability related to KCS resolved in 7 patients after SL fitting. The use of SL appears to be safe and effective in patients with severe cGVHD-related KCS refractory to conventional therapies.

1 Fred Hutchinson Cancer Research Center, Seattle, Washington

2 Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Seattle, Washington

3 University of Washington, Seattle, Washington

4 Singapore General Hospital, SingHealth, Singapore

5 Harvard Medical School and Boston Foundation for Sight, Boston, Massachusetts

Corresponding Author InformationCorrespondence and reprint requests: Mary E.D. Flowers, MD, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D5-290, Seattle, WA 98109.

PII: S1083-8791(07)00287-X

doi:10.1016/j.bbmt.2007.05.006


View previous. 7 of 19 View next.